Company profile FTRE
There is not enough data for clinical development solutions to provide analysis
There is not enough data for clinical development solutions to provide correlation calculation
There is not enough data for clinical development solutions to provide analysis
After 39 days of this quarter the interest is at 137.0. Based on that we can calculate that during remaining 52 days it will total up to 320.0. patient access solutions expected interest is significantly higher compared to previous quarter (+223.2%) and same quarter last year (+255.6%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 48 | 198 312.5% QoQ | 86 -56.6% QoQ | 104 20.9% QoQ |
| 2020 | 188 291.7% YoY 80.8% QoQ | 262 32.3% YoY 39.4% QoQ | 256 197.7% YoY -2.3% QoQ | 122 17.3% YoY -52.3% QoQ |
| 2021 | 126 -33.0% YoY 3.3% QoQ | 128 -51.1% YoY 1.6% QoQ | 46 -82.0% YoY -64.1% QoQ | 122 0.0% YoY 165.2% QoQ |
| 2022 | 51 -59.5% YoY -58.2% QoQ | 116 -9.4% YoY 127.5% QoQ | 131 184.8% YoY 12.9% QoQ | 57 -53.3% YoY -56.5% QoQ |
| 2023 | 90 76.5% YoY 57.9% QoQ | 46 -60.3% YoY -48.9% QoQ | 194 48.1% YoY 321.7% QoQ | 99 73.7% YoY -49.0% QoQ |
| 2024 | 137 52.2% YoY 38.4% QoQ | - | - | - |
The average 5 years interest of patient access solutions was 9.99 per week. The last year interest of patient access solutions compared to the last 5 years has changed by 6.61%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 9.91%.
After 39 days of this quarter the interest is at 169.0. Based on that we can calculate that during remaining 52 days it will total up to 394.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 93 | 202 117.2% QoQ | 205 1.5% QoQ | 274 33.7% QoQ |
| 2020 | 204 119.4% YoY -25.5% QoQ | 273 35.1% YoY 33.8% QoQ | 361 76.1% YoY 32.2% QoQ | 220 -19.7% YoY -39.1% QoQ |
| 2021 | 221 8.3% YoY 0.5% QoQ | 372 36.3% YoY 68.3% QoQ | 334 -7.5% YoY -10.2% QoQ | 290 31.8% YoY -13.2% QoQ |
| 2022 | 402 81.9% YoY 38.6% QoQ | 438 17.7% YoY 9.0% QoQ | 469 40.4% YoY 7.1% QoQ | 398 37.2% YoY -15.1% QoQ |
| 2023 | 494 22.9% YoY 24.1% QoQ | 455 3.9% YoY -7.9% QoQ | 550 17.3% YoY 20.9% QoQ | 509 27.9% YoY -7.5% QoQ |
| 2024 | 169 -65.8% YoY -66.8% QoQ | - | - | - |
The average 5 years interest of life sciences industry was 26.56 per week. The last year interest of life sciences industry compared to the last 5 years has changed by 41.19%. The interest for life sciences industry is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 128.1%.
After 39 days of this quarter the interest is at 25.0. Based on that we can calculate that during remaining 52 days it will total up to 58.0. Fortrea Holdings expected interest is significantly lower compared to same quarter last year (-53.6%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 29 | 69 137.9% QoQ | 55 -20.3% QoQ | 24 -56.4% QoQ |
| 2020 | 49 69.0% YoY 104.2% QoQ | 41 -40.6% YoY -16.3% QoQ | 41 -25.5% YoY 0.0% QoQ | 18 -25.0% YoY -56.1% QoQ |
| 2021 | 51 4.1% YoY 183.3% QoQ | 19 -53.7% YoY -62.7% QoQ | 160 290.2% YoY 742.1% QoQ | 127 605.6% YoY -20.6% QoQ |
| 2022 | 48 -5.9% YoY -62.2% QoQ | 19 0.0% YoY -60.4% QoQ | 49 -69.4% YoY 157.9% QoQ | 81 -36.2% YoY 65.3% QoQ |
| 2023 | 125 160.4% YoY 54.3% QoQ | 55 189.5% YoY -56.0% QoQ | 177 261.2% YoY 221.8% QoQ | 44 -45.7% YoY -75.1% QoQ |
| 2024 | 25 -80.0% YoY -43.2% QoQ | - | - | - |
The average 5 years interest of Fortrea Holdings was 5.0 per week. The last year interest of Fortrea Holdings compared to the last 5 years has changed by 50.4%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 121.18%.
There is not enough data for phase I-IV clinical trial management to provide analysis
There is not enough data for phase I-IV clinical trial management to provide correlation calculation
There is not enough data for phase I-IV clinical trial management to provide analysis
After 39 days of this quarter the interest is at 357.0. Based on that we can calculate that during remaining 52 days it will total up to 833.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 582 | 798 37.1% QoQ | 980 22.8% QoQ | 903 -7.9% QoQ |
| 2020 | 960 64.9% YoY 6.3% QoQ | 838 5.0% YoY -12.7% QoQ | 903 -7.9% YoY 7.8% QoQ | 774 -14.3% YoY -14.3% QoQ |
| 2021 | 789 -17.8% YoY 1.9% QoQ | 697 -16.8% YoY -11.7% QoQ | 784 -13.2% YoY 12.5% QoQ | 725 -6.3% YoY -7.5% QoQ |
| 2022 | 843 6.8% YoY 16.3% QoQ | 753 8.0% YoY -10.7% QoQ | 874 11.5% YoY 16.1% QoQ | 720 -0.7% YoY -17.6% QoQ |
| 2023 | 849 0.7% YoY 17.9% QoQ | 746 -0.9% YoY -12.1% QoQ | 765 -12.5% YoY 2.5% QoQ | 789 9.6% YoY 3.1% QoQ |
| 2024 | 357 -58.0% YoY -54.8% QoQ | - | - | - |
The average 5 years interest of clinical pharmacology was 62.95 per week. The last year interest of clinical pharmacology compared to the last 5 years has changed by -5.21%. The interest for clinical pharmacology is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by -14.64%.
After 39 days of this quarter the interest is at 267.0. Based on that we can calculate that during remaining 52 days it will total up to 623.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 275 | 405 47.3% QoQ | 354 -12.6% QoQ | 367 3.7% QoQ |
| 2020 | 468 70.2% YoY 27.5% QoQ | 516 27.4% YoY 10.3% QoQ | 357 0.8% YoY -30.8% QoQ | 559 52.3% YoY 56.6% QoQ |
| 2021 | 444 -5.1% YoY -20.6% QoQ | 440 -14.7% YoY -0.9% QoQ | 363 1.7% YoY -17.5% QoQ | 393 -29.7% YoY 8.3% QoQ |
| 2022 | 376 -15.3% YoY -4.3% QoQ | 453 3.0% YoY 20.5% QoQ | 380 4.7% YoY -16.1% QoQ | 531 35.1% YoY 39.7% QoQ |
| 2023 | 689 83.2% YoY 29.8% QoQ | 485 7.1% YoY -29.6% QoQ | 395 3.9% YoY -18.6% QoQ | 453 -14.7% YoY 14.7% QoQ |
| 2024 | 267 -61.2% YoY -41.1% QoQ | - | - | - |
The average 5 years interest of trial solutions was 34.37 per week. The last year interest of trial solutions compared to the last 5 years has changed by 13.03%. The interest for trial solutions is seasonal. The last year interest is quite higher compared to 5 years ago. It has increased by 27.29%.
There is not enough data for post approval services to provide analysis
There is not enough data for post approval services to provide correlation calculation
There is not enough data for post approval services to provide analysis
After 39 days of this quarter the interest is at 160.0. Based on that we can calculate that during remaining 52 days it will total up to 373.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 135 | 288 113.3% QoQ | 148 -48.6% QoQ | 146 -1.4% QoQ |
| 2020 | 146 8.1% YoY 0.0% QoQ | 162 -43.8% YoY 11.0% QoQ | 185 25.0% YoY 14.2% QoQ | 213 45.9% YoY 15.1% QoQ |
| 2021 | 196 34.2% YoY -8.0% QoQ | 151 -6.8% YoY -23.0% QoQ | 215 16.2% YoY 42.4% QoQ | 79 -62.9% YoY -63.3% QoQ |
| 2022 | 183 -6.6% YoY 131.6% QoQ | 180 19.2% YoY -1.6% QoQ | 221 2.8% YoY 22.8% QoQ | 235 197.5% YoY 6.3% QoQ |
| 2023 | 270 47.5% YoY 14.9% QoQ | 195 8.3% YoY -27.8% QoQ | 239 8.1% YoY 22.6% QoQ | 339 44.3% YoY 41.8% QoQ |
| 2024 | 160 -40.7% YoY -52.8% QoQ | - | - | - |
The average 5 years interest of pharmaceutical organizations was 15.66 per week. The last year interest of pharmaceutical organizations compared to the last 5 years has changed by 35.06%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 50.64%.
There is not enough data for biotechnology organizations to provide analysis
There is not enough data for biotechnology organizations to provide correlation calculation
There is not enough data for biotechnology organizations to provide analysis
There is not enough data for medical device organizations. to provide analysis
There is not enough data for medical device organizations. to provide correlation calculation
There is not enough data for medical device organizations. to provide analysis